Opinion
Video
Biomarkers and Therapeutic Impact on PIRA
Author(s):
Key Takeaways
- Biomarkers of PIRA in MS are essential for understanding disease mechanisms and guiding treatment strategies.
- Inflammatory signatures in cerebrospinal fluid and peripheral blood offer insights into PIRA's pathophysiology.
Panelists discuss how recent investigations into progression independent of relapse activity (PIRA) in multiple sclerosis (MS) have revealed complex inflammatory signatures in cerebrospinal fluid and peripheral blood, with biomarkers like neurofilament light chain and pro-inflammatory cytokines showing promise in tracking neurodegeneration. The Swedish MS Registry’s findings suggest that early implementation of high-efficacy disease-modifying therapies may effectively delay or prevent PIRA progression, though these results require further robust, multicenter validation to definitively establish clinical significance and generalizability.
Video content above is prompted by the following:
- What is our understanding of biomarkers of PIRA? What do we know about inflammatory signatures in the cerebrospinal fluid and peripheral blood of patients with PIRA?
- Findings from the Swedish MS Registry show that early use of high vs medium efficacy disease-modifying therapy may be effective in delaying or preventing PIRA. Are these differences meaningful? Do you have any concerns about this study?
Related Videos
Related Content
